IL2 and melanoma: When intrathecal IL-2 therapy fails, other innovative strategies have been investigated, such as educated cytotoxic T lymphocytes (cyt-T cells) after the interaction with autologous dendritic cells charged with different melanoma antigens (melanoma-associated antigens tyrosinase, Melan-A/MART, gp100/Pmel17).